| __timestamp | Pharming Group N.V. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4042025 | 504755000 |
| Thursday, January 1, 2015 | 5279557 | 838526000 |
| Friday, January 1, 2016 | 8073913 | 1177697000 |
| Sunday, January 1, 2017 | 44864073 | 1320433000 |
| Monday, January 1, 2018 | 53488904 | 1556200000 |
| Tuesday, January 1, 2019 | 65896361 | 1834800000 |
| Wednesday, January 1, 2020 | 69968267 | 1346000000 |
| Friday, January 1, 2021 | 92047281 | 1824900000 |
| Saturday, January 1, 2022 | 131819000 | 2115900000 |
| Sunday, January 1, 2023 | 87501000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Data in motion
In the competitive world of biotechnology, operational efficiency is key. This analysis of Selling, General, and Administrative (SG&A) expenses from 2014 to 2023 reveals intriguing insights into the financial strategies of Regeneron Pharmaceuticals, Inc. and Pharming Group N.V. Over this period, Regeneron consistently outspent Pharming, with its SG&A expenses peaking at approximately $2.63 billion in 2023, a staggering 30% increase from 2022. In contrast, Pharming's expenses showed a more modest growth, reaching around $87.5 million in 2023, after a peak in 2022. This disparity highlights Regeneron's aggressive investment in operational activities, potentially fueling its market dominance. Meanwhile, Pharming's more conservative approach may reflect a strategic focus on cost management. As the biotech landscape evolves, these financial strategies could significantly impact each company's competitive positioning.
Pfizer Inc. or Regeneron Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. or Viatris Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Exelixis, Inc.
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG Trends and Insights
Regeneron Pharmaceuticals, Inc. or Ligand Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Novavax, Inc.
SG&A Efficiency Analysis: Comparing Insmed Incorporated and Pharming Group N.V.
Ascendis Pharma A/S and Pharming Group N.V.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Pharming Group N.V. vs Veracyte, Inc.
Pharming Group N.V. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Pharming Group N.V. and Ligand Pharmaceuticals Incorporated